Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes.

Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes.
复制标题

DOI:
10.1155/2014/751859
复制
发表时间:
2014
影响因子:
2.8
通讯作者:
Dang N
Dang N
中科院分区:
医学4区
文献类型:
--
作者:
Ding L;Pang S;Sun Y;Tian Y;Yu L;Dang N

文献摘要

参考文献

被引文献

相似文献

2 型糖尿病 (T2D) 是最常见的代谢性疾病,许多人都患有由高血糖和血脂异常引起的并发症。核受体 (NR) 是配体诱导的转录因子,可介导体内代谢途径的变化。作为代谢调节因子,法尼醇X受体(FXR)和肝脏X受体(LXR)在T2D的发病机制中发挥着关键作用,其发病机制仍有待详细阐明。在此,我们回顾了 FXR 和 LXR 在调节胆汁酸、脂质和葡萄糖代谢中的生理和病理生理作用及其对 T2D 的影响的最新进展,考虑到这两种核受体是治疗 T2D 及其并发症的潜在药物靶点。
Type 2 diabetes (T2D) is the most prevalent metabolic disease, and many people are suffering from its complications driven by hyperglycaemia and dyslipidaemia. Nuclear receptors (NRs) are ligand-inducible transcription factors that mediate changes to metabolic pathways within the body. As metabolic regulators, the farnesoid X receptor (FXR) and the liver X receptor (LXR) play key roles in the pathogenesis of T2D, which remains to be clarified in detail. Here we review the recent progress concerning the physiological and pathophysiological roles of FXRs and LXRs in the regulation of bile acid, lipid and glucose metabolism and the implications in T2D, taking into account that these two nuclear receptors are potential pharmaceutical targets for the treatment of T2D and its complications.
DOI: 10.1053/gast.2001.25503
发表时间: 2001-07-01
期刊: GASTROENTEROLOGY
影响因子: 29.4
作者:
Denson, LA;Sturm, E;Karpen, SJ
通讯作者: Karpen, SJ
DOI: 10.1074/jbc.m210208200
发表时间: 2003-01-10
影响因子: 4.8
作者:
Cao, GQ;Liang, Y;Etgen, GJ
通讯作者: Etgen, GJ
DOI: 10.1194/jlr.m300135-jlr200
发表时间: 2003-11-01
影响因子: 6.5
作者:
Chisholm, JW;Hong, J;Lawn, RM
通讯作者: Lawn, RM
DOI: 10.1210/me.2007-0568
发表时间: 2008-10-01
影响因子: --
作者:
Chuang, Jen-Chieh;Cha, Ji-Young;Repa, Joyce J.
通讯作者: Repa, Joyce J.
DOI: 10.1074/jbc.m207903200
发表时间: 2003-05-30
影响因子: 4.8
作者:
Chen, F;Ma, L;Shneider, BL
通讯作者: Shneider, BL